In vivo Thermoacoustic Imaging of HER2 Status

HER2 状态的体内热声成像

• 批准号: 7189579
• 负责人: ROBERT A KRUGER
• 金额: $ 80.69万
• 依托单位: OPTOSONICS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-07 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7189579
• 关键词: bioimaging /biomedical imaging; biomarker; biomedical equipment development; breast neoplasm /cancer diagnosis; dyes; immunoconjugates; infrared radiation; molecular /cellular imaging; monoclonal antibody; oxyhemoglobin; phantom model; protooncogene; reagent /indicator; technology /technique development; thermography; tomography; ultrasonography

DESCRIPTION (provided by applicant): In this Fast Track application, we propose developing the novel imaging technology and molecular probe that will enable the non-invasive detection and quantification of HER2 overexpression in breast cancers. The approach we are promoting is to label Herceptin, a therapeutic mono-clonal antibody, with an infraredabsorbing dye, and then to detect the presence of the anitbody/dye conjugate with thermoacoustic computed tomography (TCT) using multi-spectral infrared stimulation. In Phase I we will validate a muIti-spectral decomposition technique for quantifying the presence of an infrared-absorbing dye in the presence of varying amounts of oxygenated and deoxygenated blood. We will also quantify the minimum detectable concentration of dye within a 1-ml volume through a series of tissue-mimicking phantom studies. In Phase II we will collaborate with researchers at Indiana University Medical Center to develop the molecular probe and quantify its binding to HER2 expressing cells. We will also modify our imaging instrumentation to allow us to acquire ultrasound and thermoacoustic CT images, which will be in perfect spatjal registration. Mice will be used to validate our approach in several tumor models with the data collected and equipment developed used to build the foundation for transferring the technology to humans. Our specific Phase I aims: 1. Design, construct and test a TCT imaging system that incorporates a spherically focused, semi-circular detector array. 2. Validate a multi-spectral decomposition technique using this new TCT imaging system for quantifying the concentration of IRIS Green One dye in the presence of oxy- and deoxy-hemoglobin. 3. Determine the minimum detectable concentration of IRIS Green One dye that can be detected within a 1.2-mm diameter tube in a breast-tissue mimicking phantom.

描述（由申请人提供）： 在这个快速通道应用中，我们建议开发新的成像技术和分子探针，使乳腺癌中HER 2过表达的非侵入性检测和定量成为可能。我们正在推广的方法是用红外吸收染料标记治疗性单克隆抗体赫赛汀，然后用热声计算机断层扫描（TCT）使用多光谱红外刺激检测抗体/染料缀合物的存在。在第一阶段，我们将验证一种多光谱分解技术，用于在存在不同量的含氧和脱氧血液的情况下量化红外吸收染料的存在。我们还将通过一系列组织模拟体模研究，量化1 ml体积内染料的最小可检测浓度。 在第二阶段，我们将与印第安纳州大学医学中心的研究人员合作，开发分子探针并定量其与HER 2表达细胞的结合。 我们还将修改我们的成像仪器，使我们能够获得超声和热声CT图像，这将是完美的spatjal注册。小鼠将用于在几种肿瘤模型中验证我们的方法，收集的数据和开发的设备用于为将该技术转移到人类奠定基础。 第一阶段的具体目标是： 1.设计、构建和测试TCT成像系统，该系统包含球形聚焦的半圆形探测器阵列。 2.在氧合血红蛋白和脱氧血红蛋白存在的情况下，使用这种新的TCT成像系统来定量IRIS绿色One染料的浓度。 3.确定在乳房组织模拟体模中直径为1.2 mm的管中可检测到的IRIS绿色1染料的最小可检测浓度。